news
DMD drug trial shows regulatory flexibility is possible for rare diseases
Mindy Leffler, whose son has Duchenne muscular dystrophy (DMD), wrote an opinion piece arguing for regulatory flexibility in rare disease drug trials. She points to the Capricor Therapeutics' Duchenne drug trial as an example where small study design decisions made a big difference, showing rigor doesn't have to be sacrificed.
Mindy Leffler, whose son has Duchenne muscular dystrophy (DMD), wrote an opinion piece arguing for regulatory flexibility in rare disease drug trials. She points to the Capricor Therapeutics' Duchenne drug trial as an example where small study design decisions made a big difference, showing rigor doesn't have to be sacrificed.
The architecture take
I’ve heard the argument many times: rare diseases need special rules, because gathering enough trial participants is just too hard. But this piece, coming from a parent, points to something else: the FDA and other regulators actually can be flexible without lowering standards. It's about smart study design, not just cutting corners. For conditions like Duchenne, where every day counts, getting a drug to market quicker makes a huge difference. I worry about what this means for other conditions, though. Regulators might not apply this same logic to therapies for less urgent, but still debilitating, chronic illnesses affecting millions. The mechanism here is simply faster access to drugs that could preserve muscle tissue and extend life. What to watch? Whether this 'regulatory flexibility' becomes a precedent for other therapeutic areas or remains an outlier.